Gordon Brown, DO, Summit Health, breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG and the potential for a paradigm shift in treatment.
He also previews upcoming trials like POTOMAC and KEYNOTE-676 that could further reshape the standard of care.